Those generic cough drops you tossed in your cart without a second thought might be part of a nationwide recall, after federal regulators raised red flags about how they were made overseas.
Multiple private-label cough drops sold across the U.S. have been voluntarily pulled from shelves after regulators identified manufacturing problems at the supplier. The affected products include store-brand packs sold under Exchange Select, Caring Mill, MGC Health and QC/Quality Choice labels, among others.
The recall began March 20, 2026, when the manufacturer, Xiamen Kang Zhongyuan Biotechnology Co., Ltd., agreed to take back multiple lots after an FDA inspection turned up observations that could affect product quality. The agency classified the action as a Class II recall, which means exposure may cause temporary or medically reversible adverse health consequences, and the timeline and scope are laid out by the MedShadow Foundation.
Named labels include Exchange Select 30-count packs sold through military exchanges, Caring Mill Cherry 90-count distributed by FSA Store Inc., and several MGC Health and QC/Quality Choice varieties. Specific lot numbers, UPCs and expiration dates are listed in the recall notice. For example, the Caring Mill Cherry 90-count appears under lot 20241030 with an Oct. 30, 2026 expiration date, as reported by KFOR. Consumers are being urged to check packages before use and compare lot and UPC details against the agency list.
Check UPCs and lot numbers
The FDA enforcement report itemizes affected SKUs, UPCs and expiration dates so buyers can confirm whether a particular bag is involved. The agency’s entry calls out Exchange Select, Caring Mill, Discount Drug Mart, MGC Health and QC Quality Choice among the private-label lots in the recall. For the full table of affected UPCs and lot numbers, see the FDA Enforcement Report.
Why the agency recommended the recall
According to a summary from MedShadow, the FDA recommended the voluntary recall after an Aug. 15, 2025 inspection of the Xiamen facility uncovered observations that “may affect product quality.” Those findings led distributors and retailers to remove the named lots as a precaution, and so far reporting has not tied the recall to any widespread illnesses. The MedShadow Foundation recap also points to the enforcement entry and notes the agency’s Class II designation.
What to do if you bought the products
If any of the listed packages are sitting in your medicine cabinet, stop using them and match the lot and UPC on your bag to the details in the agency notice and retailer advisories. Retailers and distributors have been asked to pull affected lots from shelves; customers can return products to the place of purchase for a refund or disposal and should hang on to receipts if they plan to request reimbursement, as noted in consumer reporting.
If you or someone else has a reaction after using one of the lozenges, contact Poison Control at 1-800-222-1222 and consider filing a report with the FDA’s MedWatch program.
Supply-chain note
The situation is a reminder that many store brands are quietly made in the same third-party factories, so a single quality issue can ripple across dozens of labels at once. Xiamen Kang Zhongyuan appears as the labeler on multiple NDC entries for over-the-counter lozenges, underscoring how one supplier problem can spread through the retail ecosystem. For individual product label records, see entries on DailyMed.
